WO2022180447A1 - Method for eliminating specific pathogenic microorganisms in the body - Google Patents
Method for eliminating specific pathogenic microorganisms in the body Download PDFInfo
- Publication number
- WO2022180447A1 WO2022180447A1 PCT/IB2022/000017 IB2022000017W WO2022180447A1 WO 2022180447 A1 WO2022180447 A1 WO 2022180447A1 IB 2022000017 W IB2022000017 W IB 2022000017W WO 2022180447 A1 WO2022180447 A1 WO 2022180447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganisms
- expression
- oxidation
- enos
- human body
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 244000000010 microbial pathogen Species 0.000 title 1
- 244000005700 microbiome Species 0.000 claims abstract description 70
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 53
- 230000003647 oxidation Effects 0.000 claims abstract description 52
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 230000006378 damage Effects 0.000 claims abstract description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 18
- 239000011707 mineral Substances 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 12
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 235000010755 mineral Nutrition 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 11
- 230000002776 aggregation Effects 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 206010030113 Oedema Diseases 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 9
- 210000001772 blood platelet Anatomy 0.000 claims description 9
- 239000013589 supplement Substances 0.000 claims description 9
- 239000011573 trace mineral Substances 0.000 claims description 9
- 235000013619 trace mineral Nutrition 0.000 claims description 9
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 229940050410 gluconate Drugs 0.000 claims description 8
- 235000020776 essential amino acid Nutrition 0.000 claims description 7
- 239000003797 essential amino acid Substances 0.000 claims description 7
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 claims description 5
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims description 5
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000003969 glutathione Nutrition 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 239000011647 vitamin D3 Substances 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940021056 vitamin d3 Drugs 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- 238000004159 blood analysis Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 230000003313 weakening effect Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 abstract description 53
- 230000008569 process Effects 0.000 abstract description 18
- 210000000987 immune system Anatomy 0.000 abstract description 15
- 241000700605 Viruses Species 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 38
- 239000000047 product Substances 0.000 description 21
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 16
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 229930064664 L-arginine Natural products 0.000 description 8
- 235000014852 L-arginine Nutrition 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 208000025721 COVID-19 Diseases 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- -1 L-Citruline aminoacid Chemical class 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 229930003761 Vitamin B9 Natural products 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000005842 biochemical reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 235000007635 levomefolic acid Nutrition 0.000 description 4
- 239000011578 levomefolic acid Substances 0.000 description 4
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 235000019159 vitamin B9 Nutrition 0.000 description 4
- 239000011727 vitamin B9 Substances 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- FCASKLHVRFDIJB-UHFFFAOYSA-N Riboflavine Natural products Cc1cc2N=C3C(NC(=O)NC3=O)N(CC(O)C(O)C(O)CO)c2cc1C FCASKLHVRFDIJB-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RUFJTBOKWJYXPM-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-hydroxybutanedioic acid Chemical compound OC(=O)C(O)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N RUFJTBOKWJYXPM-WCCKRBBISA-N 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N 2-azaniumyl-5-[(n'-methylcarbamimidoyl)amino]pentanoate Chemical compound CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000020806 vegan diet Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
Definitions
- the present invention relates to a method for eliminating selected microorganisms of one or several types within the human body and, more particularly, to a combined method for eliminating microorganisms within the human body that requires a mechanical pre-damage of the pathogens capsule, secondly intake of a safe dose of an external oxidant, plus parallel supplements that invoke controlled eNOS-expression (ROS/RNS) for a determined time, as a result producing internal radical oxidation/nitric species in the body.
- ROS/RNS controlled eNOS-expression
- the method further includes a second step including penetrating the damaged hulls of the pathogens with a safe dose of an external and parallel internal produced oxidation species to eliminate the microorganism.
- the external oxidation product may include chlorine dioxide in a watery solution (at a dose generally recognized as safe).
- the internally oxidation product is produced inside of the body as ROS (radical oxygen/oxide species), and/or RNS (radical nitrogen/nitric species), this results in a shifting of uncontrolled NO gas production from iNOS(induced Nitric Oxide Synthase) - expression towards controlled NO gas production from eNOS (endothelial Nitric Oxide Synthase) - expression.
- eNOS-expression is capable to do the oxidation effect on the damaged hulls of the damaged microorganisms.
- This new method uses the intentional invoked eNOS-expression (using Vitamins B2,B3,B9,Zn Zinc, Fe Iron, and amino acids L- Arginine and L-Citruline) as a tool to reduce the free radicals in the body such as the dangerous Superoxide 0-, Peroxynitrite ONOO-, Dinitro-trioxide N203 radicals, which would cause damage to the human cells if uncontrolled NO (Nitric Oxide) production is invoked from macrophages, or neutrophilic granulocytes or inflammatory interleukines causing iNOS-expression with 1000 times the NO production as in eNOS-expression.
- eNOS-expression using Vitamins B2,B3,B9,Zn Zinc, Fe Iron, and amino acids L- Arginine and L-Citruline
- the vitamins B2 (Riboflavine), B3 (Niacine), B9 (Folic Acid) [actually a derivate from vitamin B9 which is called BH4 “Tetrahydrobiopterin” and is formed from vitamin B9 inside of the body] are required for the donation of electrons in this biochemical process, it forms BH3+ and is recycled to BH4.
- Zinc forms with a Hem (iron) group a so called “dimere” which is required for eNOS-expression.
- Oxygen as 02 will react in this systems to donate Oxygen, forming NO gas and the B-vitamins electrons e- which are absorbed from receptors of the L- Arginine and forming NO Nictric Oxide as a gas and L-Citruline aminoacid as the reaction products.
- the NO as a gas is the internal oxidation product we used.
- the L-Citruline is recycled to L-Arginine.
- the method further includes a third step terminating and reducing the two different oxidation processes by providing antioxidants in form of Vitamin C and Vitamin E to neutralize the external oxidant CL02 within 20 minutes.
- TH2 is the antagonist for ROS/RNS production or TH1 dominance. So if the shifting towards TH2 is initiated the production of the internal NO gas using eNOS-expression or ROS/RNS radical species is reduced, stopping the internal oxidation process and activating the TH2 of the immune system, leading to the increased production of antibodies and the application of B-cells of the immune systems defense.
- a fourth step includes determining deficiencies within the body using a NLS system or laboratory blood analysis and supplementing the missing elements selectively according to the deficiencies encountered, thereby strengthening the immune system by providing the missing educts for biochemical reactions, such supplements as essential amino acids in an aqueous solutions as well as, vitamins, minerals, trace-elements and co-enzymes etc. to the human body.
- Applicant believes that a related reference corresponds to U.S. patent No. 7,165,451 issued for a detection of inorganic acid and biologic structures using resonant acoustic and/or resonant acoustic-EM energy. Applicant believes that another related reference corresponds to U.S. patent No. 5,658,322 issued for a system and method for generating bio-active frequencies. The generated frequencies are used to advantage in health science applications such as killing microorganisms and viruses and enhancing tissue generation.
- the cited references differ from the present invention because they fail to evenly destroy different sizes of the same present pathogen type, to disclose the combination of using resonant frequency treatment to pre-damage the hull of a pathogen and then introducing an oxidation step to eliminate a specific type of pathogen. None of them is capable to bring inflammations, thrombus, edemas caused from iNOS-expression under control, with its dramatic damaging effects inside of the body, nor do they explicitly strengthen the immune system to take over control again after the treatment.
- the viruses are oxidized in a way so they cannot multiply anymore.
- a further object of this invention is the intentional stop of the oxidation process and invoking TH2 shifting leading to the increased production of antibodies of the immune system and B- cells to fight the pathogens.
- Figure 1 represents a flow chart for a method 10 including a first step 20, a second step 40, a third step 60 and a fourth step 80 in accordance to an embodiment of the present invention.
- a method 10 for eliminating selectively microorganisms which basically include a first step 20, a second step 40, a third step 60, and a fourth step 80.
- First step 20 includes measuring frequencies of pathogens and applying a varying resonance frequency to the pathogens according to existing different sizes etc. This step is accomplished through an analytic electronic method with electrodes.
- the electrodes emit DC current induced at discrete frequencies by stepping up in discrete selected steps within a frequency band, offering vibration energy to the pathogens. If resonance is offered and achieved for a certain pathogen it is able to start to vibrate using this offered energy at a maximum amplitude. It is then measured the frequency that results resonance and how much energy is absorbed from these pathogens that start to vibrate at this specific resonance frequency. This physical effect is known as prior art in the field of resonant frequencies and pathogens.
- Every microorganism of a specific type and size has a discrete resonance frequency and will vibrate in its first harmonic resonance frequency form at maximum amplitude, in the present method, if an electromagnetic wave or current is applied at this resonance frequency.
- the offered vibrations energy which is applied to provide a certain level of intensity is partially absorbed by the microorganism and transformed into heat and further into mechanical fatigue in the hull/capsule. If the vibrations are applied long enough the capsule of the microorganism will even rupture. This damage effect is known as “fatigue”.
- a variable resonant frequency band should therefore be applied to the pathogens to evenly fatigue all of the pathogens. This effect can be applied to the pathogens until the microorganism eventually explode and everything within the microorganism is released and the microorganisms will eventually die.
- the present invention utilizes this fatigue effect; however, the fatigue effect is only applied to produce a small defect in the hull in form of a pre damage/crack/weakness, which is sufficient if combined with the second oxidation step to destroy the pathogen. The fatigue effect is not used to completely destroy the microorganisms hull or capsule at this step.
- Human cells are known to have a resonant frequency around eight million Hertz and microorganisms and pathogens are known to have a resonant frequency mostly below 2 million Hertz. As a result, no damage is done to human cells during the process of applying the resonant frequencies to the microorganisms and pathogens.
- a frequency of 200,000 Hertz using discrete steps of 1000 Hertz for detecting the resonance frequency of a microorganism. It is known that the human body may contain a large number of different microorganisms therein and that in order for a disease to develop symptoms or illness a certain threshold of microorganisms need to be exceeded.
- a peak of absorption of energy indicates the presence of a big amount of the same microorganism type even though the immune system is fighting to control it.
- the threshold depends on the type of microorganism and symptoms/illness level.
- a relation is made as to the resonant frequency of the microorganisms and the illness/symptoms.
- a standard frequency generator is used to generate a frequency band which is half of the discrete step width (here it was 1000 Hz steps), so from +- 500 Hertz around the measured absorption frequency.
- the frequency generator begins at 199,500 Hertz and steps up to 200,500 Hertz, by stepping up every second by 1 Hertz. One complete stepping up and down is called a cycle.
- the frequency generator is attached to an antenna or contact electrodes which apply a maximum of 15 VDC output.
- the antenna or contact electrodes are applied to a patient and the process is repeated several times/cycles to produce small defects/cracks/weaknesses in the hulls of microorganisms, but sufficiently profound. This process takes considerably less time than attempting to completely rupture all the different sized cells of the microorganisms using only this process.
- Second step 40 includes penetrating the damaged hulls of the microorganism with a low dose of an ingested external oxidation product and an oxidation product generated inside the body as an eNOS-expression (ROS /RNS).
- ROS /RNS an eNOS-expression
- the present method provides a solution to the problems involved in the use of disinfection products.
- the present invention applies a very low dose of an external ingested disinfection product plus, in parallel invokes internal oxidation / nitric species being produced, known as eNOS-expression, towards the fatigued hulls of the microorganisms and thereby selectively destroys them preferably easier due to the crack or damage or local weakness in the capsule.
- eNOS-expression internal oxidation / nitric species being produced
- the double lipid membrane of the microorganisms is more easily penetrated due to their fatigued/weakened nature and allows for oxidation to take place for the guanine of the ARN (ribo nuclein acid) or ADN (desoxiribo nuclein acid) of the microorganism.
- the microorganisms of a virus do not have a cellular core nor a metabolism of its own.
- the viral microorganisms contain ADN or ARN within the cellular hull which need to invade a human cell in order to reproduce. Additionally, both the ADN and ARN of the microorganisms include a guanine base.
- the present invention utilizes external ingestion of chlorine dioxide (CI02) in a watery solution and eNOS-expression to change the guanine base into a guanine- oxidized base.
- the present invention introduces chlorine dioxide (CI02) in an aqueous solution of 0.75 ppm (which is below 0,8 ppm, which is generally recognized as safe by the FDA). 5 drops of 3000- ppm chlorine dioxide (CI02) are given to 1 liter of water resulting in 0.75 ppm drinkable solution. 1 ccm of 3000 ppm equals 20 drops or 3 mg, so 5 drops give a 0.75 mg/ltr or 0.75 ppm concentration.
- first step 20, second step 40, a third step 60 and a fourth step 80 may be used in different cases to eliminate SARS-CoV 2 and control Covid-19.
- the antenna or electrodes cycle the measured and programmed resonance frequencies by stepping up and stepping down several cycles that are applied to the human body, the external oxidation is done in a way of drinking every 30 minutes a glass of water containing 0.75 ppm C102 in watery solution.
- the eNOS expression is started at the same time, by supplementing the following listed products at the same time, this is ingested together with the CL02 in watery solution:
- Vitamin B3 (NAD, Niacine)
- Vitamin B9 Fralic acid
- 5-MTHF 5-Methyl Tetra Hydro Folate
- Vitamin B2 (Riboflavine)
- Vitamin B3 (NAD, Niacine),
- Vitamin B9 Fralic acid
- 5-MTHF 5-Methyl Tetra Hydro Folate
- L-Citruline-Malate (amino acid), a product from eNOS- expression bio-chemical reaction (besides the NO), reduces iNOS and brings NO hyperexpression and the high radical production of superoxide 0-, peroxinitrite ONOO- and dinitro-trioxide N203 back under control.
- Method 10 further includes a third step 60 which involves terminating the oxidation process, which was initiated from second step 40 by a way of introducing antioxidants using Vitamin E (800 i.U), Vitamin C (500 mg), to stop the oxidation of the CL02 external oxidation product.
- Vitamin E 800 i.U
- Vitamin C 500 mg
- method 10 includes inducing the oxidation effect during the day and terminating the oxidation effect latest at night, half an hour before the patient goes to bed.
- steps 20 and 40 are applied. As soon as the symptoms of Covid-19 reduce, the ingestion of external C102 in watery solution and the eNOS expression is still kept up for another 2 hours, as described above. If the treatment was intended to be done and the patient did not show any symptoms but was positively tested on SARS-CoV2, then step 20 and 40 is sustained for max. 3 hours as a preventive measure to show the effect of eliminating the SARS-CoV2 and preventing Covid-19. Afterwards, after another hour after the last intake of the oxidation products, step 60 is activated using antioxidants and TH2 shifting.
- the products that work for step 60 are a combination of Vitamin E, Vitamin C, Glutathion amino acid, MnSOD (Manganese Super Oxide Dismutase, supplementing the metal manganese, MnSOD is produced in the body) in form of Mn gluconate, and ZnSOD (Zinc Super Oxide Dismutase, supplementing the zinc, ZnSOD is produced in the body) in form of Zn gluconate.
- MnSOD Manganese Super Oxide Dismutase, supplementing the metal manganese, MnSOD is produced in the body
- ZnSOD Zinc Super Oxide Dismutase, supplementing the zinc, ZnSOD is produced in the body
- Antibodies are proteins, which are synthesized in the lymph cells using amino acids.
- the 20 amino acids used contain 8 essential and 12 non-essential amino acids.
- the 12 non- essential amino acids can be synthesized inside the body if sufficient essential amino acids, minerals, vitamins, co-enzymes trace-elements and co-factors are available.
- a low protein diet can lead to these amino acid deficiencies.
- vegan or vegetarian diets lead to a depletion of B-Vitamins etc. Doing no exercise or no sports leads to a low level of antioxidants leading to eNOS uncoupling due to the lack of free radical neutralization.
- Parasites might lead to depletion of available metals (iron, hemoglobin, and zinc etc) and vitamins/minerals etc. in the body for bio-chemical reactions and might lead to the blockage of available L-Arginine to prevent their own destruction from eNOS expression (using elevated Arginase release).
- a lack of L-Arginine causes eNOS-uncoupling and iNOS-expression as well as the production of dangerous Superoxide and Peroxinitrite and Dinitro-Trioxide.
- ADMA asymmetric di methyl arginine
- Method 10 may be implemented for various applications and is not limited to SARS-CoV 2, Corona Virus.
- Other applications include using method 10 on cases of Herpes, Dengue, Malaria and other known microorganisms, in special antibiotic resistant or even multi -resistant pathogens or even in case of mutations where successful vaccines are not effective anymore. This is especially important in respect to Covid-19, because vaccines only protect to a certain point and with the present method people that get infected after the vaccination can be detoxified from SARS-Cov2. New mutations of the virus can also easily be eliminated, adopting if necessary the frequency band. The virus has no chance to escape the mechanical fatigue and the chemical oxidation process.
- Method 10 allows a user to target any specific microorganism and eliminate them using the oxidation process, together with the resonance frequencies and combined oxidation steps, the intentional stop of the oxidation process and then activating of TH2 shifting (and the production of antibodies and B-cells) and finally the strengthening of the immune system supplementing the missing educts.
- the method for eliminating microorganisms has several embodiments for industrial applicability.
- the method allows a medical practitioner to selectively target pathogen types to be eliminated while leaving the good microorganisms unharmed.
- the medical practitioner may take control over inflammations associated with aggregation of thrombocytes that leads to thrombus, edemas and sepsis caused by NO poisoning or iNOS-expression with the high liberation of peroxinitrite ONOO-superoxide O- and dinitro-tri oxide N203.
- the method is capable of eliminating pathogens of the same population but that may vary in size, length, diameter, and age efficiently and much faster than other methods with far less side effects.
- the method for eliminating microorganisms is capable of leaving non-threatening microorganisms untouched independent of apparatus producers or producers of the chemical watery solution of C102 or supplements like essential amino acids, vitamins, minerals, trace-elements and co-enzymes etc..
- the method provides a synergetic effect that only the disclosed steps of the method provide.
- the invoked eNOS expression using L-Citruline leads to the possibility to take control caused by an eNOS -uncoupling leading to iNOS-expression, hyper inflammation, aggregation of thrombocytes leading to thrombus and edemas and sepsis, caused by a 1000 times production of NO, superoxide O-, peroxinitrite ONOO- and dinitro-trioxide N203.
- the method intentionally stops the oxidation process and the invocation of the TH2 shift that leads to the increased production of antibodies of the immune system and B -cells to fight the pathogens.
- the method for eliminating microorganisms allows to selectively neutralize pathogens.
- the method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly.
- the method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS).
- the external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression.
- the method further includes a third step to deliberately terminating the activated oxidation processes.
- a fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The method for eliminating microorganisms, allows to selectively neutralize pathogens. The method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly. The method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS). The external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression. The method further includes a third step to deliberately terminating the activated oxidation processes. A fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.
Description
I. TITLE : METHOD FOR ELIMINA TING SPECIFIC PA THOGENIC
MICROORGANISMS IN THE BODY
II. BACKGROUND OF THE INVENTION
1. Field of the Invention.
[001] The present invention relates to a method for eliminating selected microorganisms of one or several types within the human body and, more particularly, to a combined method for eliminating microorganisms within the human body that requires a mechanical pre-damage of the pathogens capsule, secondly intake of a safe dose of an external oxidant, plus parallel supplements that invoke controlled eNOS-expression (ROS/RNS) for a determined time, as a result producing internal radical oxidation/nitric species in the body. During eNOS-expression, the uncontrolled NO production from iNOS-expression causing fever, inflammation, formation of thrombocyte aggregation (thrombus, oedems) is brought back under control and aggregations are dissolved, sepsis is stopped. Thirdly the end of the oxidation period is intentionally invoked using antioxidants and provoking TH2 shifting, supporting the production of antibodies. Lastly, fourthly providing measures, strengthening the immune system with the supplementation of measured deficiencies of amino acids, vitamins, minerals, trace-elements, co-enzyms etc.
2. Description of the Related Art.
[002] Several designs for a method for eliminating microorganisms within the human body have been designed in the past. None of them, however, include a method for eliminating microorganisms and their induced organism which selectively kills microorganisms in the human body in such an effective, fast, and soft manner. The method includes a first step which determinates the frequencies of vibrations at resonance of pathogens within a human body. The pathogens are then applied a slow cycling resonant frequency band to mechanically and evenly pre-damage the hulls of the different sized and formed family members of the same microorganism type.
[003] The method further includes a second step including penetrating the damaged hulls of the pathogens with a safe dose of an external and parallel internal produced oxidation species to eliminate the microorganism. The external oxidation product may include chlorine dioxide in a watery solution (at a dose generally recognized as safe). The internally oxidation product is produced inside of the body as ROS (radical oxygen/oxide species), and/or RNS (radical nitrogen/nitric species), this results in a shifting of uncontrolled NO gas production from iNOS(induced Nitric Oxide Synthase) - expression towards controlled NO gas production from eNOS (endothelial Nitric Oxide Synthase) - expression. eNOS-expression is capable to do the oxidation effect on the damaged hulls of the damaged microorganisms.
[004] This new method uses the intentional invoked eNOS-expression (using Vitamins B2,B3,B9,Zn Zinc, Fe Iron, and amino acids L- Arginine and L-Citruline) as a tool to reduce the free radicals in the body such as the dangerous Superoxide 0-, Peroxynitrite ONOO-, Dinitro-trioxide N203 radicals, which would cause damage to the human cells if uncontrolled NO (Nitric Oxide) production is invoked from macrophages, or neutrophilic granulocytes or inflammatory interleukines causing iNOS-expression with 1000 times the NO production as in eNOS-expression.
[005] In order to start eNOS-expression, the vitamins B2 (Riboflavine), B3 (Niacine), B9 (Folic Acid) [actually a derivate from vitamin B9 which is called BH4 “Tetrahydrobiopterin” and is formed from vitamin B9 inside of the body] are required for the donation of electrons in this biochemical process, it forms BH3+ and is recycled to BH4. Zinc forms with a Hem (iron) group a so called “dimere” which is required for eNOS-expression. Oxygen as 02 will react in this systems to donate Oxygen, forming NO gas and the B-vitamins electrons e- which are absorbed from receptors of the L- Arginine and forming NO Nictric Oxide as a gas and L-Citruline aminoacid as the reaction products. The NO as a gas is the internal oxidation product we used. During eNOS-expression the L-Citruline is recycled to L-Arginine. Several circumstances can lead to a so called eNOS- “uncoupling”, which leads to the production of superoxide O- instead of NO, which reacts with the existing NO gas to form peroxinitrite ONOO-, which is capable to irreversibly react with the folic acid derivate BH4 and
oxidizes it to BH2 which cannot further be used for the eNOS-expression and the uncoupling occurs. This caused uncoupling leads to iNOS expression which produces 1000 times the quantity of NO gas and leads to the hyperproduction of the radicals superoxide 0-, peroxinitrite ONOO- and dinitro- trioxide N203, which cause irreversible damage to cells, fever, formation of thrombus, edemas, inflammation and sepsis, specially with respect to Covid-19.
[006] The method further includes a third step terminating and reducing the two different oxidation processes by providing antioxidants in form of Vitamin C and Vitamin E to neutralize the external oxidant CL02 within 20 minutes. Parallel we are provoking a shifting towards TH2 (Thymus Helper Cell type 2) of the immune system supplementing Omega 3 fishoil, Vitamin K and D3. TH2 is the antagonist for ROS/RNS production or TH1 dominance. So if the shifting towards TH2 is initiated the production of the internal NO gas using eNOS-expression or ROS/RNS radical species is reduced, stopping the internal oxidation process and activating the TH2 of the immune system, leading to the increased production of antibodies and the application of B-cells of the immune systems defense.
[007] A fourth step includes determining deficiencies within the body using a NLS system or laboratory blood analysis and supplementing the missing elements selectively according to the deficiencies encountered, thereby strengthening the immune system by providing the missing educts for biochemical reactions, such supplements as essential amino acids in an aqueous solutions as well as, vitamins, minerals, trace-elements and co-enzymes etc. to the human body.
[008] It is known that there is a plurality of diseases caused by microorganisms and pathogens in medical practice. It is also known that antibiotics work only on bacteria and chemically damage or block the cell hull or capsules containing murine. Unfortunately, there is a large number of viruses and other pathogens where antibiotics do not work or where bacterial strains have already developed resistance to existing antibiotics. Additionally, many antibiotics normally do not eliminate only a specific type of pathogen. Good bacteria (of the intestinal flora for example) may also be eliminated during antibiotic treatment which may lead to further infections (molds for example) and diseases in
the future. Therefore, there is a need to selectively eliminate pathogens, not damaging the good ones. This is a crucial advantage of the invention.
[009] Applicant believes that a related reference corresponds to U.S. patent No. 7,165,451 issued for a detection of inorganic acid and biologic structures using resonant acoustic and/or resonant acoustic-EM energy. Applicant believes that another related reference corresponds to U.S. patent No. 5,658,322 issued for a system and method for generating bio-active frequencies. The generated frequencies are used to advantage in health science applications such as killing microorganisms and viruses and enhancing tissue generation.
[010] However, the cited references differ from the present invention because they fail to evenly destroy different sizes of the same present pathogen type, to disclose the combination of using resonant frequency treatment to pre-damage the hull of a pathogen and then introducing an oxidation step to eliminate a specific type of pathogen. None of them is capable to bring inflammations, thrombus, edemas caused from iNOS-expression under control, with its dramatic damaging effects inside of the body, nor do they explicitly strengthen the immune system to take over control again after the treatment. Advantageously, the viruses are oxidized in a way so they cannot multiply anymore.
[011] Other documents describing the closest subject matter provide for a number of more or less complicated features that fail to solve the problem in an efficient and economical way. None of these patents suggest the novel features of the present invention.
Ill SUMMARY OF THE INVENTION
[012] It is one of the objects of the present invention to provide a method for eliminating specific microorganisms which allows a medical practitioner to selectively target a pathogen type to be eliminated, leaving the good microorganisms untouched. At the same time allowing to taking control over the inflammations, aggregation of thrombocytes leading to thrombus, edemas and sepsis, caused
by a NO poisoning or iNOS-expression with the high liberation of peroxinitrite ONOO-, superoxide O- and dinitro-tri oxide N203.
[013] It is another object of this invention to provide a method eliminating microorganisms, which eliminates pathogens of the same population but varies in, sizes, lengths, diameters and age, efficiently and faster than other methods and with less side effects.
[014] It is still another object of the present invention to provide a method for eliminating microorganisms, that allows to selectively destroy pathogens while leaving non-threatening microorganisms untouched. That is done independent of apparatus producers or producers of the chemical watery solution of C102 or supplements like essential amino acids, vitamins, minerals, trace- elements and co-enzyms etc. .
[015] It is yet another object of this invention to provide such a method that is inexpensive to implement and maintain while retaining its effectiveness.
[016] It is yet another object of this invention to provide a synergetic effect that only the combination of the described and undertaken steps allow. This is specially the combination of the mechanical fatigue using vibrations and the oxidation process.
[017] It is still another object of this invention, that the invoked eNOS expression using L- Citruline will lead to the possibility to take over control caused by an eNOS-uncoupling leading to iNOS-expression, hyper inflammation, aggregation of thrombocytes leading to thrombus and edemas and sepsis, caused by a 1000 times production of NO, superoxide O-, peroxinitrite ONOO- and dinitro- tri oxide N203.
[018] A further object of this invention is the intentional stop of the oxidation process and invoking TH2 shifting leading to the increased production of antibodies of the immune system and B- cells to fight the pathogens.
[019] Further objects of the invention will be brought out in the following part of the specification, wherein detailed description is for the purpose of fully disclosing the invention without placing limitations thereon.
IV. BRIEF DESCRIPTION OF THE DRAWINGS
[020] With the above and other related objects in view, the invention consists in the details of construction and combination of parts as will be more fully understood from the following description, when read in conjunction with the accompanying drawings in which:
Figure 1 represents a flow chart for a method 10 including a first step 20, a second step 40, a third step 60 and a fourth step 80 in accordance to an embodiment of the present invention.
V. DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION
[021] Referring now to the drawings, where the present invention is generally referred to with numeral 10, it can be observed a method 10 for eliminating selectively microorganisms which basically include a first step 20, a second step 40, a third step 60, and a fourth step 80.
[022] First step 20 includes measuring frequencies of pathogens and applying a varying resonance frequency to the pathogens according to existing different sizes etc. This step is accomplished through an analytic electronic method with electrodes. The electrodes emit DC current induced at discrete frequencies by stepping up in discrete selected steps within a frequency band, offering vibration energy to the pathogens. If resonance is offered and achieved for a certain pathogen it is able to start to vibrate using this offered energy at a maximum amplitude. It is then measured the frequency that results resonance and how much energy is absorbed from these pathogens that start to vibrate at this specific resonance frequency. This physical effect is known as prior art in the field of
resonant frequencies and pathogens. Every microorganism of a specific type and size has a discrete resonance frequency and will vibrate in its first harmonic resonance frequency form at maximum amplitude, in the present method, if an electromagnetic wave or current is applied at this resonance frequency. The offered vibrations energy which is applied to provide a certain level of intensity is partially absorbed by the microorganism and transformed into heat and further into mechanical fatigue in the hull/capsule. If the vibrations are applied long enough the capsule of the microorganism will even rupture. This damage effect is known as “fatigue”.
[023] Pathogens of a specific type are always of varying size, length, diameter and consistency, resulting in a different mass of the pathogens and/or stiffness of the capsule. As a result, every pathogen will vibrate at a maximum amplitude and maximum intensity at a slightly different resonance frequency (This frequency omega = SQRT(c/m), c: stiffness, m: mass). If only a static frequency is applied, not all the pathogens of different mass and stiffness will vibrate with the same intensity at resonant frequency at the provided frequency and with the same amplitude of hull movement, they will not all receive the same fatigue, because the resonance frequency depends on the square root of (stiffness divided by its mass) of the pathogen. As a result, not all pathogens die or get the same level of damage/crack/weakness. A variable resonant frequency band should therefore be applied to the pathogens to evenly fatigue all of the pathogens. This effect can be applied to the pathogens until the microorganism eventually explode and everything within the microorganism is released and the microorganisms will eventually die. The present invention utilizes this fatigue effect; however, the fatigue effect is only applied to produce a small defect in the hull in form of a pre damage/crack/weakness, which is sufficient if combined with the second oxidation step to destroy the pathogen. The fatigue effect is not used to completely destroy the microorganisms hull or capsule at this step.
[024] Human cells are known to have a resonant frequency around eight million Hertz and microorganisms and pathogens are known to have a resonant frequency mostly below 2 million Hertz. As a result, no damage is done to human cells during the process of applying the resonant frequencies to the microorganisms and pathogens.
[025] For example, if we measure a frequency of 200,000 Hertz using discrete steps of 1000 Hertz for detecting the resonance frequency of a microorganism. It is known that the human body may contain a large number of different microorganisms therein and that in order for a disease to develop symptoms or illness a certain threshold of microorganisms need to be exceeded. The more pathogens of the same type that are present, the more energy is absorbed during the detection step - so speaking, a peak of absorption of energy indicates the presence of a big amount of the same microorganism type even though the immune system is fighting to control it. The threshold depends on the type of microorganism and symptoms/illness level. Using the measured frequency in combination with a polymerase chain reaction, a relation is made as to the resonant frequency of the microorganisms and the illness/symptoms. Afterwards a standard frequency generator is used to generate a frequency band which is half of the discrete step width (here it was 1000 Hz steps), so from +- 500 Hertz around the measured absorption frequency. Using different step widths require adopted bands of plus and minus ½ the step width. The smaller the discrete steps, the more precise and smaller are the selected frequency bands, leading to a more efficient pre-damage of the hull in the same time, more cycles during the same time. In this example, the frequency generator begins at 199,500 Hertz and steps up to 200,500 Hertz, by stepping up every second by 1 Hertz. One complete stepping up and down is called a cycle. The frequency generator is attached to an antenna or contact electrodes which apply a maximum of 15 VDC output. The antenna or contact electrodes are applied to a patient and the process is repeated several times/cycles to produce small defects/cracks/weaknesses in the hulls of microorganisms, but sufficiently profound. This process takes considerably less time than attempting to completely rupture all the different sized cells of the microorganisms using only this process.
[026] Second step 40 includes penetrating the damaged hulls of the microorganism with a low dose of an ingested external oxidation product and an oxidation product generated inside the body as an eNOS-expression (ROS /RNS). Normally disinfection products need a high dose in order to destroy the hull of a microorganism by their sole use. Additionally, these disinfection products are aggressive and may cause injuries if swallowed at these concentrations. However, the present method provides a solution to the problems involved in the use of disinfection products. The present invention applies a
very low dose of an external ingested disinfection product plus, in parallel invokes internal oxidation / nitric species being produced, known as eNOS-expression, towards the fatigued hulls of the microorganisms and thereby selectively destroys them preferably easier due to the crack or damage or local weakness in the capsule. In a virus for example the double lipid membrane of the microorganisms is more easily penetrated due to their fatigued/weakened nature and allows for oxidation to take place for the guanine of the ARN (ribo nuclein acid) or ADN (desoxiribo nuclein acid) of the microorganism.
[027] It is known that the microorganisms of a virus do not have a cellular core nor a metabolism of its own. The viral microorganisms contain ADN or ARN within the cellular hull which need to invade a human cell in order to reproduce. Additionally, both the ADN and ARN of the microorganisms include a guanine base. The present invention utilizes external ingestion of chlorine dioxide (CI02) in a watery solution and eNOS-expression to change the guanine base into a guanine- oxidized base. As a result of the oxidation, the code of the ARN that is built of a series of bases (3 bases = triplet or codon, form an amino acid) is interrupted because the guanine is replaced by its oxide thereby preventing the virus from multiplying again, the bio-molecular transcription process is interrupted. The present invention introduces chlorine dioxide (CI02) in an aqueous solution of 0.75 ppm (which is below 0,8 ppm, which is generally recognized as safe by the FDA). 5 drops of 3000- ppm chlorine dioxide (CI02) are given to 1 liter of water resulting in 0.75 ppm drinkable solution. 1 ccm of 3000 ppm equals 20 drops or 3 mg, so 5 drops give a 0.75 mg/ltr or 0.75 ppm concentration.
[028] The selection of this product will not affect healthy human cells as this C102 carries an oxidation potential that is lower than an oxidation potential of the healthy human cells, apart as it is applied at this low safe dose. The fatigued hulls of the microorganisms that results from first step 20 allows the product together with eNOS expression (ROS/RNS) to infiltrate the microorganisms and begin oxidation. eNOS (endothelial nitric oxide synthase). C102 has a stronger oxidation reaction if the reaction partner is acidious, so the lower the pH value (pH<7,0 is an acid), the stronger the reaction of C102. For this reason it is a selective oxidant. Only pathogens have a pH<7.0 good germs do not. Blood for example has a pH of about 7,35...7,45.
[029] In various implementations, first step 20, second step 40, a third step 60 and a fourth step 80 may be used in different cases to eliminate SARS-CoV 2 and control Covid-19.
[030] During the process of the first step 20 the antenna or electrodes cycle the measured and programmed resonance frequencies by stepping up and stepping down several cycles that are applied to the human body, the external oxidation is done in a way of drinking every 30 minutes a glass of water containing 0.75 ppm C102 in watery solution. In parallel, the eNOS expression is started at the same time, by supplementing the following listed products at the same time, this is ingested together with the CL02 in watery solution:
Initially:
2 grams of L-Citruline-Malate,
1 gram total of L-Arginine-Malate, L- Arginine HCL 100 mg of Vitamin B2 (Riboflavine),
100 mg of Vitamin B3 (NAD, Niacine),
0,8 mg of Vitamin B9 (Folic acid) or 5-MTHF (5-Methyl Tetra Hydro Folate),
25 mg of Zinc gluconate, and 25 mg Iron citrate. ( 25 mg based on Zn and Fe)
Thereafter every hour for keeping the eNOS-expression alive:
1 gram of L-Citruline-Malate
0,5 gram of L-Arginine-Malate, L-Arginine HCL
10 mg of Vitamin B2 (Riboflavine),
10 mg of Vitamin B3 (NAD, Niacine),
0,1 mg of Vitamin B9 (Folic acid) or 5-MTHF (5-Methyl Tetra Hydro Folate),
2,5 mg of Zinc gluconate, and 2,5 mg Iron citrate. ( 2,5 mg based on Zn and Fe)
[031] These values are based on the weight of a person with 80 kg weight. The amino acids are dissolved in a glass of water or swallowed in capsules as the rest of the vitamins and minerals and a glass of water is ingested together at the same time, that contains the CL02 in 0,75 ppm.
[032] The supplementation of these above products prevents the eNOS uncoupling and if it was uncoupled at the begin, to restart eNOS-expression, resulting in downgrading of uncontrolled iNOS- expression which caused inflammation and fever and the building of thrombus as an agglomeration of blood thrombocytes etc.. The eNOS-expression is able to also support to dissolve these aggregations independent of supplemental medication. L-Citruline-Malate (amino acid), a product from eNOS- expression bio-chemical reaction (besides the NO), reduces iNOS and brings NO hyperexpression and the high radical production of superoxide 0-, peroxinitrite ONOO- and dinitro-trioxide N203 back under control.
[033] Method 10 further includes a third step 60 which involves terminating the oxidation process, which was initiated from second step 40 by a way of introducing antioxidants using Vitamin E (800 i.U), Vitamin C (500 mg), to stop the oxidation of the CL02 external oxidation product.
[034] 500 mg Glutathion amino acid, MnSOD in form of 15 mg Manganese Mn gluconate (15 mg based on the metal Mn), and 15 mg ZnSOD in form of Zinc Zn gluconate (15 mg based on the metal Zn) into the human body and TH2 (Thymus Helper Cells type 2) shifting, ingesting 2000 mg Omega 3 fishoil, 2,5 mg Vitamin K (K1 + K2) together with 10.000 i.U. Vitamin D3 based on the weight of an 80 kg person.
[035] The antioxidants should not be taken during the day or before the treatment, the same is true for the products to provoke TH2 shifting, the oxidation effect resulting from second step 40 will not occur since the antioxidant and TH2 shifting will neutralize the external and internal oxidation products. As a result, method 10 includes inducing the oxidation effect during the day and terminating the oxidation effect latest at night, half an hour before the patient goes to bed.
[036] In a given treatment, steps 20 and 40 are applied. As soon as the symptoms of Covid-19 reduce, the ingestion of external C102 in watery solution and the eNOS expression is still kept up for
another 2 hours, as described above. If the treatment was intended to be done and the patient did not show any symptoms but was positively tested on SARS-CoV2, then step 20 and 40 is sustained for max. 3 hours as a preventive measure to show the effect of eliminating the SARS-CoV2 and preventing Covid-19. Afterwards, after another hour after the last intake of the oxidation products, step 60 is activated using antioxidants and TH2 shifting. The products that work for step 60 are a combination of Vitamin E, Vitamin C, Glutathion amino acid, MnSOD (Manganese Super Oxide Dismutase, supplementing the metal manganese, MnSOD is produced in the body) in form of Mn gluconate, and ZnSOD (Zinc Super Oxide Dismutase, supplementing the zinc, ZnSOD is produced in the body) in form of Zn gluconate. The doses are as explained above, are considered for a 80 kg person.
[037] Patients of Covid-19 and SARS-CoV2 then have their immune system strengthened by means of step 80, directly 20 minutes after ingesting the supplements from Step 60. During the treatment process the existing levels of amino acids, vitamins, minerals, trace-elements and co enzymes are measured and supplemented according to those measured to be lacking with adopted doses. This can be done from a blood analysis or adequate systems. It is important to detect if there are any missing levels and supplement only accordingly, physical exercise and sports also help during this replenishing step because they influence the absorption rate. It makes no sense to overfeed in means of “the more the better”, only the missing educts should be supplemented to avoid reverse side effects. It is important to understand, that vitamins, minerals, aminoacids, co-enzyms etc. contribute to the biochemical reactions of the immune system and enable it to regain strength. The exact dose is matter to the theurapeuts considerations and experiences.
[038] Part of the immune system (in TH2) develops and uses antibodies to further destroy intruded pathogens. Antibodies are proteins, which are synthesized in the lymph cells using amino acids. The 20 amino acids used contain 8 essential and 12 non-essential amino acids. The 12 non- essential amino acids can be synthesized inside the body if sufficient essential amino acids, minerals, vitamins, co-enzymes trace-elements and co-factors are available. A low protein diet can lead to these amino acid deficiencies. Vegan or vegetarian diets lead to a depletion of B-Vitamins etc. Doing no exercise or no sports leads to a low level of antioxidants leading to eNOS uncoupling due to the lack
of free radical neutralization. Parasites might lead to depletion of available metals (iron, hemoglobin, and zinc etc) and vitamins/minerals etc. in the body for bio-chemical reactions and might lead to the blockage of available L-Arginine to prevent their own destruction from eNOS expression (using elevated Arginase release). A lack of L-Arginine causes eNOS-uncoupling and iNOS-expression as well as the production of dangerous Superoxide and Peroxinitrite and Dinitro-Trioxide.
[039] The amino acids, vitamins, minerals, etc. are also often reduced from microorganisms (parasites) which invade the body. For example, evolutionary the Toxoplasmosis germ induces Arginase (an enzyme=protein) that reduces the available L-Arginine and causes uncoupling of eNOS, in order to protect itself from destruction.
[040] A similar effect of eNOS uncoupling is detected at elevated levels of ADMA (asymmetric di methyl arginine) which appears on clinical pictures such as kidney deficiencies, high blood pressure, diabetics, high triglycerides and others (factors up to 12 times to normal ADMA levels are present) that block the electron receptors on the L-Arginine. This leads to the paradox situation, that even though the L-Arginine levels are normal, still eNOS uncoupling occurs, because the L-Arginine is blocked. This is one of the reasons, why older people are more likely to develop a more severe form of Covid-19 and form part of the high-risk groups, because they have elevated ADMA levels apart from other influences resulting in iNOS-expression. The supplementation of L-Arginine and L- Citruline together is able to break this paradox and together with the explained supplementation of B- Vitamins and metals in form of organic minerals start the eNOS-expression again.
[041] Fourth step 80 ends method 10
[042] Method 10 may be implemented for various applications and is not limited to SARS-CoV 2, Corona Virus. Other applications include using method 10 on cases of Herpes, Dengue, Malaria and other known microorganisms, in special antibiotic resistant or even multi -resistant pathogens or even in case of mutations where successful vaccines are not effective anymore. This is especially important in respect to Covid-19, because vaccines only protect to a certain point and with the present method
people that get infected after the vaccination can be detoxified from SARS-Cov2. New mutations of the virus can also easily be eliminated, adopting if necessary the frequency band. The virus has no chance to escape the mechanical fatigue and the chemical oxidation process.
[043] The following list provides some examples which is not exhaustive of which types of pathogens can be eliminated this way. For example, Klebsiella Pneumoniae, Staphylococcus Aureus, Escheria Coli, EHEC etc. Also, unknown pathogens (for example the pathogens causing MERS-CoV etc.) can be detected and eliminated with this combined method, the treatment only needs to trace the frequencies of the pathogens participating, regardless of their name or origin. In case of MERS-CoV it was discovered that several microorganism work together to cause the outbreak of the illness. Tropical illnesses where the pathogen is known, but there is no medication available such as Ebola, Schistosomiasis, Leishmaniosis and others etc. can be successfully treated with this method. Method 10 allows a user to target any specific microorganism and eliminate them using the oxidation process, together with the resonance frequencies and combined oxidation steps, the intentional stop of the oxidation process and then activating of TH2 shifting (and the production of antibodies and B-cells) and finally the strengthening of the immune system supplementing the missing educts.
[044] The foregoing description conveys the best understanding of the objectives and advantages of the present invention. Different embodiments may be made of the inventive concept of this invention. It is to be understood that all matter disclosed herein is to be interpreted merely as illustrative, and not in a limiting sense.
VI. INDUSTRIAL APPLICABILITY
The method for eliminating microorganisms has several embodiments for industrial applicability. For example, the method allows a medical practitioner to selectively target pathogen types to be eliminated while leaving the good microorganisms unharmed. Concurrently, the medical practitioner may take control over inflammations associated with aggregation of thrombocytes that leads to thrombus,
edemas and sepsis caused by NO poisoning or iNOS-expression with the high liberation of peroxinitrite ONOO-superoxide O- and dinitro-tri oxide N203. In another embodiment the method is capable of eliminating pathogens of the same population but that may vary in size, length, diameter, and age efficiently and much faster than other methods with far less side effects. Furthermore, the method for eliminating microorganisms is capable of leaving non-threatening microorganisms untouched independent of apparatus producers or producers of the chemical watery solution of C102 or supplements like essential amino acids, vitamins, minerals, trace-elements and co-enzymes etc.. In yet another embodiment the method provides a synergetic effect that only the disclosed steps of the method provide. In another iteration the invoked eNOS expression using L-Citruline leads to the possibility to take control caused by an eNOS -uncoupling leading to iNOS-expression, hyper inflammation, aggregation of thrombocytes leading to thrombus and edemas and sepsis, caused by a 1000 times production of NO, superoxide O-, peroxinitrite ONOO- and dinitro-trioxide N203. In addition the method intentionally stops the oxidation process and the invocation of the TH2 shift that leads to the increased production of antibodies of the immune system and B -cells to fight the pathogens. The method for eliminating microorganisms, allows to selectively neutralize pathogens. The method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly. The method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS). The external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression. The method further includes a third step to deliberately terminating the activated oxidation processes. A fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.
Claims
1. A method for eliminating specific microorganisms, comprising: a) measuring and detecting resonant frequencies of microorganisms within a human body and applying a band of resonant frequencies to said human body through a frequency generator and antenna or contact electrodes to cause a damage, crack, or weakening of a capsule of microorganisms within the human body; b) inducing an oxidation effect to said microorganisms by ingesting an aqueous mixture of less than 0.8 ppm of Chlorine Dioxide, and simultaneously internally provoking an eNOS-expression and an internal production of NO gas over a prolonged period together with the application of the band of resonant frequencies; c) reducing an iNOS-expression and accompanied effects of fever, inflammation, aggregation of thrombocytes leading to thrombus and edemas, sepsis caused by NO-poisening, superoxide, peroxinitrite and dinitro-trioxide radicals; d) terminating said oxidation effect by ingesting antioxidant supplements including Vitamin E and Vitamin C to terminate CL02 external oxidation, said terminating of said oxidation effect further including ingesting Glutathion (Amino acid), MnSOD in form of Mn gluconate, and ZnSOD in form of Zn gluconate, and provoking a TH2 shift by ingesting Omega 3 fishoil, Vitamin K plus Vitamin D3; to control internal oxidation from ROS/RNS during TH1 and the eNOS-expression; and e) replenishing deficient amino acids in the human body with an aqueous solution of vitamins, minerals, trace-elements and co-enzymes by ingesting them.
2. The method for eliminating microorganisms of claim 1 wherein said band of resonant frequencies is plus ½ step width up and minus ½ step width down of a measured absorption frequency to form a frequency band width of the cycle.
3. The method for eliminating microorganisms of claim 1 wherein said antioxidant supplements being ingested are provided in liquid, capsule, powder or tablet form, including any combination thereof.
4. The method for eliminating microorganisms of claim 1, wherein the reduction of the uncontrolled iNOS-expression which causes fever, inflammation, and the aggregation of thrombocytes forming thrombus and edemas, is achieved by means of inducing the eNOS-expression and L-Citruline.
5. The method for eliminating microorganisms of claim 1 wherein said essential amino acids, vitamins, minerals, trace-elements and co-enzymes are adapted to refill depleted deposits within said human body which are determined according to a measurement from a laboratory blood analysis or an NLS system.
6. The method for eliminating microorganisms of claim 1 wherein said aqueous mixture contains at most 5 drops of 3000 parts per million of chlorine dioxide per liter of water resulting in 0.75 ppm C102.
7. The method for eliminating microorganisms of claim 1 wherein the terminating of the oxidation effect occurs at night, at least half an hour before entering a sleeping state.
8. A method for eliminating specific microorganisms, consisting of: a) measuring and detecting resonant frequencies of microorganisms within a human body and applying a band of resonant frequencies to said human body through a frequency generator and antenna or contact electrodes to cause a
damage, crack, or weakening of a capsule of microorganisms within the human body; b) inducing an oxidation effect to said microorganisms by ingesting an aqueous mixture containing at most 5 drops of 3000 parts per million of chlorine dioxide per liter of water resulting in 0.75 ppm C102 ingested every 30 minutes, and simultaneously internally provoking an eNOS-expression and an internal production of NO gas over a prolonged period together with the application of the band of resonant frequencies; c) reducing an iNOS-expression and accompanied effects of fever, inflammation, aggregation of thrombocytes leading to thrombus and edemas, sepsis caused by NO-poisening, superoxide, peroxinitrite and dinitro-trioxide radicals; d) terminating said oxidation effect by ingesting antioxidant supplements including Vitamin E and Vitamin C to terminate CL02 external oxidation, said terminating of said oxidation effect further including ingesting Glutathion (Amino acid), MnSOD in form of Mn gluconate, and ZnSOD in form of Zn gluconate, and provoking a TH2 shift by ingesting Omega 3 fishoil, Vitamin K plus Vitamin D3; to control internal oxidation from ROS/RNS during TH1 and the eNOS-expression; and e) replenishing deficient amino acids in the human body with an aqueous solution of vitamins, minerals, trace-elements and co-enzymes by ingesting them.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/182,664 | 2021-02-23 | ||
US17/182,664 US20220133625A1 (en) | 2020-07-13 | 2021-02-23 | Method for eliminating specific pathogenic microorganisms in the body |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022180447A1 true WO2022180447A1 (en) | 2022-09-01 |
Family
ID=80684886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/000017 WO2022180447A1 (en) | 2021-02-23 | 2022-01-19 | Method for eliminating specific pathogenic microorganisms in the body |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022180447A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0714027A2 (en) * | 1994-11-23 | 1996-05-29 | 5E Systeme für holistische Medizin Ges.m.b.H. | Apparatus and method for registering energetic information that is specific to substances and the body |
US5658322A (en) | 1995-10-11 | 1997-08-19 | Regeneration Technology | Bio-active frequency generator and method |
US7165451B1 (en) | 1998-09-11 | 2007-01-23 | Gr Intellectual Reserve, Llc | Methods for using resonant acoustic and/or resonant acousto-EM energy to detect and/or effect structures |
RU66205U1 (en) * | 2007-02-16 | 2007-09-10 | Анатолий Филиппович Подкопаев | DEVICE FOR GENERATING A FREQUENCY SPECTRUM PULSE GROUP |
DE202009006244U1 (en) * | 2009-04-30 | 2009-07-16 | Baklayan, Alan | bioresonance |
-
2022
- 2022-01-19 WO PCT/IB2022/000017 patent/WO2022180447A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0714027A2 (en) * | 1994-11-23 | 1996-05-29 | 5E Systeme für holistische Medizin Ges.m.b.H. | Apparatus and method for registering energetic information that is specific to substances and the body |
US5658322A (en) | 1995-10-11 | 1997-08-19 | Regeneration Technology | Bio-active frequency generator and method |
US7165451B1 (en) | 1998-09-11 | 2007-01-23 | Gr Intellectual Reserve, Llc | Methods for using resonant acoustic and/or resonant acousto-EM energy to detect and/or effect structures |
RU66205U1 (en) * | 2007-02-16 | 2007-09-10 | Анатолий Филиппович Подкопаев | DEVICE FOR GENERATING A FREQUENCY SPECTRUM PULSE GROUP |
DE202009006244U1 (en) * | 2009-04-30 | 2009-07-16 | Baklayan, Alan | bioresonance |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lisi et al. | Nitric oxide to fight viral infections | |
JP2010051963A (en) | Drink containing high-concentration hydrogen-dissolved water | |
Prentice | Iron metabolism, malaria, and other infections: what is all the fuss about? | |
JP2005126384A (en) | Pharmacologically functional water and its use | |
EP2289496A3 (en) | Non-gelatin soft capsule system | |
WO2003002466A1 (en) | Method for antioxidation and antioxidative functional water | |
WO2007010422A3 (en) | Apparatus and method for defibrillation with pulse detection using electromagnetic waves | |
US20100008850A1 (en) | Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container | |
Gurton et al. | Sodium bicarbonate ingestion improves time-to-exhaustion cycling performance and alters estimated energy system contribution: a dose-response investigation | |
Bell et al. | Nonlinear response amplification mechanisms for low doses of natural product nanomedicines: dynamical interactions with the recipient complex adaptive system | |
US20220133625A1 (en) | Method for eliminating specific pathogenic microorganisms in the body | |
WO2022180447A1 (en) | Method for eliminating specific pathogenic microorganisms in the body | |
Van Buiten et al. | Elemental iron modifies the redox environment of the gastrointestinal tract: a novel therapeutic target and test for metabolic syndrome | |
Cho et al. | Effects of chitooligosaccharide lactate salt on sleep deprivation-induced fatigue in mice | |
Khan et al. | Application of nanoparticles in oral hygiene | |
Haider Iqbal et al. | Antioxidants: A Brief Review | |
Li et al. | Conditioned taste aversion as instrumental punishment. | |
FR3024019A1 (en) | FOOD SUPPLEMENT FOR IMPROVING THE FUNCTIONING OF LIVING CELLS AND ASSOCIATED METHOD | |
Russell | A Study into the Biological Activity and Therapeutic Potential of Molecular Hydrogen and Oxyhydrogen Gases. | |
Idkaidek et al. | Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach | |
Qaid et al. | Study of Vitamin C amount in pharmaceutical industries and its matching with manufacturer’s specifications in the prospectus for different companies | |
CN102309443B (en) | Small cluster water zinc supplementation oral liquid, and preparation method and application thereof | |
CN105596362A (en) | Energy liquid powder mineral supplement and activation method | |
Bhatt et al. | Acceptance of the Nanotechnology in the Food Industry for customer Satisfaction | |
Freye et al. | ATC Malachlorite® for treatment of patients with acute Plasmodium falciparum infection: A pilot study incorporating 500 patients in the rural area of Cameroon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22709366 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22709366 Country of ref document: EP Kind code of ref document: A1 |